⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 15, 2019Journal of Clinical InvestigationOpen Access

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Biogen Inc.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Furie et al. (2019) studied this question.

synapsesocial.com/papers/69dd387299c691022d99b66c https://doi.org/10.1172/jci124466

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1Advances in understanding the role of type I interferons in systemic lupus erythematosusGenetic Association Study · 2014 · 125 citations
2Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9Original Research · 2010 · 205 citations
3CD303 (BDCA‐2) signals in plasmacytoid dendritic cells <i>via</i> a BCR‐like signalosome involving Syk, Slp65 and PLCγ2Original Research · 2007 · 107 citations
4Anti‐ <scp>BDCA</scp> 2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc‐dependent and Fc‐independent mechanismsOriginal Research · 2015 · 121 citations